Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 09 Jul 2022
Pfizer and BioNTech announce U.S. FDA approval of their COVID-19 vaccine Comirnaty for adolescents 12 through 15 years of age
8 July 2022 - Approval of the two dose primary series is based on the totality of data through six months ...
Posted by Michael Wonder on 08 Jul 2022
NICE recommends Opdivo as post-surgery treatment
8 July 2021 - The therapy will be used for specific muscle invasive urothelial cancer patients ...
Posted by Michael Wonder on 08 Jul 2022
World’s first chemo drone delivery announced on NHS birthday
5 July 2022 - NHS cancer patients will be the first in the world to benefit from chemotherapy delivered by ...
Posted by Michael Wonder on 08 Jul 2022
Doctors, pharmacists call for better support to prescribe anti-virals
8 July 2022 - Pandemic measures including home delivery of medicines and subsidised Telehealth appointments should be reinstated to allow ...
Posted by Michael Wonder on 07 Jul 2022
US FDA awards rare paediatric disease designation to paxalisib for AT/RT, a rare form of childhood brain cancer
6 July 2022 - Kazia Therapeutics is pleased to announce that the U.S. FDA has awarded rare paediatric disease designation ...
Posted by Michael Wonder on 07 Jul 2022
MSAC updates agenda for July 2022 meeting
7 July 2022 - One application has been added. ...
Posted by Michael Wonder on 07 Jul 2022
Testing for differences in survival when treatment effects are persistent, decaying, or delayed
7 July 2022 - A statistical test for the presence of treatment effects on survival will be based on a null ...
Posted by Michael Wonder on 07 Jul 2022
Vertex announces letter of intent with the pan-Canadian Pharmaceutical Alliance for public reimbursement of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children with cystic fibrosis ages 6 and older
7 July 2022 - Vertex Pharmaceuticals today announced that it has signed a letter of intent with the pan-Canadian Pharmaceutical ...
Posted by Michael Wonder on 07 Jul 2022
EMA finalises companion diagnostic guidance
7 July 2022 - The EMA) has finalised guidance on companion diagnostics, addressing procedural aspects to facilitate consultation between EMA ...
Posted by Michael Wonder on 07 Jul 2022
PHARMAC keeps medical devices role despite failing to curb costs
8 July 2022 - The government is persisting with a way of buying hugely expensive medical devices that has been proven ...
Posted by Michael Wonder on 07 Jul 2022
Accelerated approval - taking the FDA’s concerns seriously
6 July 2022 - User-fee re-authorisation creates new opportunities for the FDA to address issues with its accelerated-approval program, including the ...
Posted by Michael Wonder on 07 Jul 2022
Expanded eligibility for fourth COVID-19 vaccine dose
7 July 2022 - An additional 7.4 million people will now be eligible to receive a fourth COVID-19 vaccine dose ...
Posted by Michael Wonder on 07 Jul 2022
ATAGI updated recommendations for a winter dose of COVID-19 vaccine
7 July 2022 - ATAGI has updated its recommendations for a winter dose of COVID-19 vaccine to help reduce severe ...
Posted by Michael Wonder on 06 Jul 2022
FDA authorises pharmacists to prescribe Paxlovid with certain limitations
6 July 2022 - New prescribing authority could improve access for some patients at high risk for severe COVID-19. ...
Posted by Michael Wonder on 06 Jul 2022
NICE recommends Janssen’s treatment for active psoriatic arthritis
6 July 2022 - Clinical trial evidence suggests that Tremfya is effective when compared with a placebo ...